Comparisons of in-hospital complications between total hip arthroplasty and hip resurfacing arthroplasty.

Hip resurfacing arthroplasty In-hospital complications Nationwide inpatient sample database Osteoarthritis Total hip arthroplasty

Journal

BMC musculoskeletal disorders
ISSN: 1471-2474
Titre abrégé: BMC Musculoskelet Disord
Pays: England
ID NLM: 100968565

Informations de publication

Date de publication:
11 May 2023
Historique:
received: 10 10 2022
accepted: 03 05 2023
medline: 15 5 2023
pubmed: 12 5 2023
entrez: 11 5 2023
Statut: epublish

Résumé

Hip resurfacing arthroplasty (HRA) is a less common but effective alternative method to total hip arthroplasty (THA) for hip reconstruction. In this study, we investigated the incidences of in-hospital complications between patients who had been subjected to THA and HRA. The National Inpatient Sample data that had been recorded from 2005 to 2014 was used in this study. Based on the International Classification of Disease, Ninth Revision, Clinical Modification, patients who underwent THA or HRA were included. Data on demographics, preoperative comorbidities, length of hospital stay, total charges, and in-hospital mortality and complications were compared. Multiple logistic regression analysis was used to determine whether different surgical options are independent risk factors for postoperative complications. A total of 537,506 THAs and 9,744 HRAs were obtained from the NIS database. Patients who had been subjected to HRA exhibited less preoperative comorbidity rates, shorter length of stay and extra hospital charges. Moreover, HRA was associated with more in-hospital prosthesis loosening. Notably, patients who underwent HRA were younger and presented less preoperative comorbidities but did not show lower incidences in most complications. The popularity of HRA gradually reduced from the year 2005 to 2014. Patients who underwent HRA were more likely to be younger, male, have less comorbidities and spend more money on medical costs. The risk of in-hospital prosthesis loosening after HRA was higher. The HRA-associated advantages with regards to most in-hospital complications were not markedly different from those of THA. In-hospital complications of HRA deserve more attention from surgeons.

Sections du résumé

BACKGROUND BACKGROUND
Hip resurfacing arthroplasty (HRA) is a less common but effective alternative method to total hip arthroplasty (THA) for hip reconstruction. In this study, we investigated the incidences of in-hospital complications between patients who had been subjected to THA and HRA.
METHODS METHODS
The National Inpatient Sample data that had been recorded from 2005 to 2014 was used in this study. Based on the International Classification of Disease, Ninth Revision, Clinical Modification, patients who underwent THA or HRA were included. Data on demographics, preoperative comorbidities, length of hospital stay, total charges, and in-hospital mortality and complications were compared. Multiple logistic regression analysis was used to determine whether different surgical options are independent risk factors for postoperative complications.
RESULTS RESULTS
A total of 537,506 THAs and 9,744 HRAs were obtained from the NIS database. Patients who had been subjected to HRA exhibited less preoperative comorbidity rates, shorter length of stay and extra hospital charges. Moreover, HRA was associated with more in-hospital prosthesis loosening. Notably, patients who underwent HRA were younger and presented less preoperative comorbidities but did not show lower incidences in most complications.
CONCLUSIONS CONCLUSIONS
The popularity of HRA gradually reduced from the year 2005 to 2014. Patients who underwent HRA were more likely to be younger, male, have less comorbidities and spend more money on medical costs. The risk of in-hospital prosthesis loosening after HRA was higher. The HRA-associated advantages with regards to most in-hospital complications were not markedly different from those of THA. In-hospital complications of HRA deserve more attention from surgeons.

Identifiants

pubmed: 37170240
doi: 10.1186/s12891-023-06487-7
pii: 10.1186/s12891-023-06487-7
pmc: PMC10173641
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

375

Subventions

Organisme : Natural Science Foundation of Guangdong Province
ID : 2021A1515011628
Organisme : Science and Technology Program of Guangzhou
ID : 202102020957

Informations de copyright

© 2023. The Author(s).

Références

Orthopedics. 2010 Sep;33(9 Suppl):11-3
pubmed: 20839716
Hip Int. 2012 Mar-Apr;22(2):195-202
pubmed: 22547372
Orthop Clin North Am. 2005 Apr;36(2):187-93, ix
pubmed: 15833456
J Bone Joint Surg Br. 2004 Mar;86(2):177-84
pubmed: 15046429
J Bone Joint Surg Am. 2006 Nov;88 Suppl 3:90-7
pubmed: 17079373
BMJ. 2013 Nov 27;347:f6549
pubmed: 24284336
J Am Acad Orthop Surg. 2004 Sep-Oct;12(5):314-21
pubmed: 15469226
J Bone Joint Surg Am. 2008 Mar;90(3):637-54
pubmed: 18310716
Clin Orthop Relat Res. 2013 Jan;471(1):201-5
pubmed: 22528384
J Bone Joint Surg Br. 2008 Jul;90(7):847-51
pubmed: 18591590
Bone Joint J. 2018 Oct;100-B(10):1320-1329
pubmed: 30295530
Curr Rev Musculoskelet Med. 2016 Mar;9(1):84-92
pubmed: 26830851
Lancet. 2018 Nov 3;392(10158):1662-1671
pubmed: 30496081
BMJ. 2012 Oct 03;345:e6688
pubmed: 23034862
Int Orthop. 2018 Oct;42(10):2323-2327
pubmed: 29455347
Int Orthop. 2012 Jan;36(1):27-34
pubmed: 21647734
Medicine (Baltimore). 2019 May;98(18):e15513
pubmed: 31045842
J Arthroplasty. 2021 Sep;36(9):3200-3208
pubmed: 33992480
Surg Technol Int. 2014 Mar;24:326-32
pubmed: 24347481
Int Orthop. 2015 Oct;39(10):2031-6
pubmed: 25708400
Int Orthop. 2011 Feb;35(2):231-7
pubmed: 21079954
Orthop Traumatol Surg Res. 2017 Sep;103(5):675-678
pubmed: 28552834
Orthop J Sports Med. 2021 May 06;9(5):23259671211003521
pubmed: 33997077
Bull NYU Hosp Jt Dis. 2009;67(2):108-12
pubmed: 19583535
Hip Int. 2014 Oct 02;24 Suppl 10:S19-24
pubmed: 24970031
Clin Orthop Relat Res. 2015 Dec;473(12):3770-8
pubmed: 25981716
J Bone Joint Surg Br. 2005 Feb;87(2):167-70
pubmed: 15736736
Hip Int. 2015 Jul-Aug;25(4):330-8
pubmed: 26109156
Clin Orthop Relat Res. 2020 Nov;478(11):2625-2636
pubmed: 32898048
J Bone Joint Surg Am. 2018 Nov 7;100(21):1879-1887
pubmed: 30399083
BMJ. 2012 Feb 28;344:e1349
pubmed: 22374740
BMJ. 2012 Jun 14;344:e3319
pubmed: 22700782
Clin Orthop Relat Res. 2015 Aug;473(8):2521-9
pubmed: 25758375
Int Orthop. 2021 Dec;45(12):3075-3081
pubmed: 34155524
J Arthroplasty. 2021 Mar;36(3):1055-1059
pubmed: 33183915
J Orthop. 2020 Dec 31;23:123-127
pubmed: 33488008
Lancet. 2012 Nov 17;380(9855):1759-66
pubmed: 23036895

Auteurs

Yuanyuan Huang (Y)

School of Health, Dongguan Polytechnic, Dongguan, Guangdong, 523000, China.

Qinfeng Yang (Q)

Division of Orthopaedic Surgery, Department of Orthopaedics, Nanfang Hospital, Southern Medical University, 1838 Guangzhou Avenue, Guangzhou, Guangdong, 510515, China.

Ziqi Wang (Z)

Division of Orthopaedic Surgery, Department of Orthopaedics, Nanfang Hospital, Southern Medical University, 1838 Guangzhou Avenue, Guangzhou, Guangdong, 510515, China.

Zhijie Pan (Z)

Division of Orthopaedic Surgery, Department of Orthopaedics, Nanfang Hospital, Southern Medical University, 1838 Guangzhou Avenue, Guangzhou, Guangdong, 510515, China.

Yang Zhang (Y)

Division of Orthopaedic Surgery, Department of Orthopaedics, Nanfang Hospital, Southern Medical University, 1838 Guangzhou Avenue, Guangzhou, Guangdong, 510515, China. nfgjzy@126.com.

Zhanjun Shi (Z)

Division of Orthopaedic Surgery, Department of Orthopaedics, Nanfang Hospital, Southern Medical University, 1838 Guangzhou Avenue, Guangzhou, Guangdong, 510515, China. nfgksdy@163.com.

Sheng Yang (S)

Division of Orthopaedic Surgery, Department of Orthopaedics, Nanfang Hospital, Southern Medical University, 1838 Guangzhou Avenue, Guangzhou, Guangdong, 510515, China. yangdashuai15@163.com.
The First School of Clinical Medicine, Southern Medical University, Guangzhou, Guangdong, 510515, China. yangdashuai15@163.com.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH